S2 Genomics develops and sells the Singulator, a benchtop platform that automates reproducible, rapid tissue dissociations into single cell or nuclei suspensions for single cell genomics. The Singulator platform comprises a benchtop instrument, single-use consumables, and more than 80 validated protocols for preparing samples from different tissue types. Customers use nuclei and high-viability cell suspensions produced by the Singulator to advance neuroscience and oncology research. Since its first commercial launch in 2020, the Singulator has been adopted globally by academic research organizations, pharmaceutical companies, biotech firms and service providers. Management states the platform removes a major bottleneck for conducting single cell genomics research and enables more scientists to process more samples. The company is based in Livermore, California and recently completed a Series A financing to support commercial growth and new applications for the platform.

Total raised

$16M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2024